Antibodies against insulin-like growth factor i receptor and uses thereof

Abstract

Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing said antibodies, and uses for such antibodies are disclosed. Such antibodies are implicated in antitumor therapy.

1 . A purified monoclonal antibody that binds to the IGF-IR which comprises
 a heavy chain comprising
 a first complementarity determining region consisting of amino acids 31 to 35 of said heavy chain, 
 a second complementarity determining region consisting of amino acids 50 to 66 of said heavy chain, and 
 a third complementarity determining region consisting of amino acids 99 to 107 of said heavy chain,
 wherein said first complementarity determining region has an amino acid sequence selected from group consisting of amino acids 31 to 35 of SEQ ID NO:1 and amino acids 31 to 35 of SEQ ID NO:3; wherein said second complementarity determining region has an amino acid sequence selected from group consisting of amino acids 50 to 66 of SEQ ID NO:1 and amino acids 50 to 66 of SEQ ID NO:3; and wherein said third complementarity determining region has an amino acid sequence selected from group consisting of amino acids 99 to 107 of SEQ ID NO:1 and amino acids 99 to 107 of SEQ ID NO:3; and 
 
   a light chain comprising
 a first light chain complementarity determining region consisting of amino acids 24 to 34 of said light chain, 
 a second light chain complementarity determining region consisting of amino acids 50 to 56 of said light chain, and 
 a third light chain complementarity determining region consisting of amino acids 89 to 98 of said light chain,
 wherein said first light chain complementarity determining region has an amino acid sequence selected from group consisting of amino acids 24 to 34 of SEQ ID NO:2 and amino acids 24 to 34 of SEQ ID NO:4; wherein said second light chain complementarity determining region has an amino acid sequence selected from group consisting of amino acids 50 to 56 of SEQ ID NO:2 and amino acids 50 to 56 of SEQ ID NO:4; and wherein said third light chain complementarity determining region has an amino acid sequence selected from group consisting of amino acids 89 to 98 of SEQ ID NO:2 and amino acids 89 to 98 of SEQ ID NO:4. 
 
   
     
     
         2 . A purified monoclonal antibody that binds to the IGF-IR which comprises
 a heavy chain comprising
 a first complementarity determining region consisting of amino acids 31 to 35 of said heavy chain having an amino acid sequence consisting of amino acids 31 to 35 of SEQ ID NO:1, 
 a second complementarity determining region consisting of amino acids 50 to 66 of said heavy chain having an amino acid sequence consisting of amino acids 50 to 66 of SEQ ID NO:1, and 
 a third complementarity determining region consisting of amino acids 99 to 107 of said heavy chain having an amino acid sequence consisting of amino acids 99 to 107 of SEQ ID NO:1; and 
   a light chain comprising
 a first light chain complementarity determining region consisting of amino acids 24 to 34 of said light chain having an amino acid sequence consisting of amino acids 24 to 34 of SEQ ID NO:2, 
 a second light chain complementarity determining region consisting of amino acids 50 to 56 of said light chain having an amino acid sequence consisting of amino acids 50 to 56 of SEQ ID NO:2, and 
 a third light chain complementarity determining region consisting of amino acids 89 to 98 of said light chain having an amino acid sequence consisting of amino acids 89 to 98 of SEQ ID NO:2. 
   
     
     
         3 . A purified monoclonal antibody that binds to the IGF-IR which comprises
 a heavy chain comprising
 a first complementarity determining region consisting of amino acids 31 to 35 of said heavy chain having an amino acid sequence consisting of amino acids 31 to 35 of SEQ ID NO:3, 
 a second complementarity determining region consisting of amino acids 50 to 66 of said heavy chain having an amino acid sequence consisting of amino acids 50 to 66 of SEQ ID NO:3, and 
 a third complementarity determining region consisting of amino acids 99 to 107 of said heavy chain having an amino acid sequence consisting of amino acids 99 to 107 of SEQ ID NO:3; and 
   a light chain comprising
 a first light chain complementarity determining region consisting of amino acids 24 to 34 of said light chain having an amino acid sequence consisting of amino acids 24 to 34 of SEQ ID NO:4, 
 a second light chain complementarity determining region consisting of amino acids 50 to 56 of said light chain having an amino acid sequence consisting of amino acids 50 to 56 of SEQ ID NO:4, and 
 a third light chain complementarity determining region consisting of amino acids 89 to 98 of said light chain having an amino acid sequence consisting of amino acids 89 to 98 of SEQ ID NO:4. 
   
     
     
         4 . A purified monoclonal antibody according to  claim 2  that binds to the IGF-IR which comprises
 a heavy chain comprising SEQ ID NO:1 and   a light chain comprising SEQ ID NO:2.   
     
     
         5 . A purified monoclonal antibody according to  claim 3  that binds to the IGF-IR which comprises
 a heavy chain comprising SEQ ID NO:3 and   a light chain comprising SEQ ID NO:4.   
     
     
         6 . The antibody of  claim 1  comprising an antibody derived from a member selected from the group consisting of hybridoma cell line <IGF-1R> HUMAB Clone 18 with accession number DSM ACC 2587 and hybridoma cell line <IGF-1R> HUMAB Clone 22 with accession number DSM ACC 2594. 
     
     
         7 . A hybridoma cell line selected from the group consisting of hybridoma cell line <IGF-1R> HUMAB Clone 18 with accession number DSM ACC 2587 and hybridoma cell line <IGF-1R> HUMAB Clone 22 with accession number DSM ACC 2594.